Bioengineering of Antibody Fragments: Challenges and Opportunities

Sama Pirkalkhoran,Wiktoria Roksana Grabowska,Hamid Heidari Kashkoli,Reihaneh Mirhassani,David Guiliano,Colin Dolphin,Hanieh Khalili

DOI: https://doi.org/10.3390/bioengineering10020122

IF: 5.046

2023-01-17

Bioengineering

Abstract:Antibody fragments are used in the clinic as important therapeutic proteins for treatment of indications where better tissue penetration and less immunogenic molecules are needed. Several expression platforms have been employed for the production of these recombinant proteins, from which E. coli and CHO cell-based systems have emerged as the most promising hosts for higher expression. Because antibody fragments such as Fabs and scFvs are smaller than traditional antibody structures and do not require specific patterns of glycosylation decoration for therapeutic efficacy, it is possible to express them in systems with reduced post-translational modification capacity and high expression yield, for example, in plant and insect cell-based systems. In this review, we describe different bioengineering technologies along with their opportunities and difficulties to manufacture antibody fragments with consideration of stability, efficacy and safety for humans. There is still potential for a new production technology with a view of being simple, fast and cost-effective while maintaining the stability and efficacy of biotherapeutic fragments.